Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 22, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 32.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 24 concluded trials, 75% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 22, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| February 15, 2027 | A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Trial Milestone | Phase 1 |
| December 15, 2027 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2029 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | Trial Milestone | Phase 3 |
Track SNDX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SNDX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.